Schwartz Investment Counsel’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $512K | Buy |
975
+175
| +22% | +$91.9K | 0.02% | 107 |
|
|
2025
Q1 | $507K | Hold |
800
| – | – | 0.02% | 109 |
|
|
2024
Q4 | $570K | Buy |
800
+400
| +100% | +$285K | 0.02% | 111 |
|
|
2024
Q3 | $420K | Hold |
400
| – | – | 0.02% | 117 |
|
|
2024
Q2 | $420K | Hold |
400
| – | – | 0.02% | 119 |
|
|
2024
Q1 | $385K | Hold |
400
| – | – | 0.01% | 129 |
|
|
2023
Q4 | $351K | Hold |
400
| – | – | 0.01% | 127 |
|
|
2023
Q3 | $329K | Sell |
400
-325
| -45% | -$267K | 0.01% | 128 |
|
|
2023
Q2 | $521K | Hold |
725
| – | – | 0.02% | 118 |
|
|
2023
Q1 | $596K | Hold |
725
| – | – | 0.03% | 117 |
|
|
2022
Q4 | $523K | Hold |
725
| – | – | 0.02% | 117 |
|
|
2022
Q3 | $499K | Hold |
725
| – | – | 0.03% | 110 |
|
|
2022
Q2 | $429K | Hold |
725
| – | – | 0.02% | 117 |
|
|
2022
Q1 | $506K | Hold |
725
| – | – | 0.02% | 117 |
|
|
2021
Q4 | $458K | Buy |
725
+175
| +32% | +$111K | 0.02% | 118 |
|
|
2021
Q3 | $333K | Hold |
550
| – | – | 0.01% | 120 |
|
|
2021
Q2 | $307K | Hold |
550
| – | – | 0.01% | 122 |
|
|
2021
Q1 | $260K | Buy |
+550
| New | +$260K | 0.01% | 122 |
|